News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Prima Biomed (PRR.AX) Conference Call to Discuss First Half of Fiscal Year 2013 Results



3/5/2013 9:22:17 AM

SYDNEY, AUSTRALIA--(Marketwire - March 04, 2013) - Prima BioMed Ltd (ASX: PRR) (NASDAQ: PBMD) (ISIN: US74154B2034) ("Prima," "the Company") today announced it will hold a conference call to discuss its results for the first half of its fiscal year 2013, the period from July 1 through December 31, 2012. The half year report was previously released on the 28th of February 2013 and is available through the Investor Relations section of the Company's website at www.primabiomed.com.au.

The call is scheduled for Thursday, the 7th of March 2013 at 9:00am (Sydney local time). Conference call dial-in numbers are as follows:

Australia Toll Free
1 800 131 617

Australia Alternate Toll Free
1 800 838 758

USA & Canada
1 855 237 2970

Germany
0800 189 9369

The call will also be audio webcast with additional supplemental slides available via http://services.choruscall.com/links/primabiomed130306.html. Before launching the webcast, it is recommended to click on the link and then on "test your systems configuration."

A replay of the teleconference and webcast will be available through Prima's website following the live event.

About Prima BioMed
Prima BioMed is a globally active biotechnology company. As a leader in personalized bio-therapeutic products for cancer, Prima is dedicated to leveraging its current technology and expertise to develop innovative treatment options for patients and maximize value to shareholders. Prima's lead product is CVac™, an autologous dendritic cell product currently in clinical trials for ovarian cancer patients who are in remission.


For further information please contact:

USA Investor/Media:
Ms. Jessica Brown
Prima BioMed Ltd.
+1 (919) 710-9061
Email Contact

Australia Investor/Media:
Mr. James Moses
Mandate Corporate
+61 (0) 420 991 574
Email Contact

Europe Investor/Media:
Mr. Axel Muhlhaus
edicto GmbH
+49 (0) 69 905505-52
Email Contact


Read at BioSpace.com


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES